Phase I/II – Other

643 trials 280 recruiting

Filter these 643 trials by condition, country, sponsor and more.

Open in Search →

Oxytocin and attachment development: Looking beyond the expected? Recruiting

2024-518004-49-00 Healthy children 2025-10-28
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and… Recruiting

2024-517140-65-00 Multiple Myeloma (MM). 2025-10-23
Neoadjuvant Cemiplimab Plus Imiquimod in Cutaneous Basal Cell Carcinoma. Recruiting

2025-520698-38-00 Cutaneous Basal Cell Carcinoma 2025-10-22
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Relapsed or Refractory B-Cell Malignancies 2025-10-15
Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line trea… Recruiting

2024-511459-16-00 Histologically confirmed pancreatic adenocarcinoma with 2025-10-14
Evaluation of Multiparametric dynamic whole-body 68Ga-PSMA PET imaging for Hepatocellular Carcinoma recurrence. HIMIKO study. Recruiting

2024-515178-28-00 Hepatocellular carcinoma 2025-09-23
Towards improved therapy selection and targeted treatment for nasopharyngeal carcinoma. A proof-of-concept pilot study for somatostatin rece… Recruiting

2025-520689-23-00 nasopharyngeal carcinoma 2025-09-22
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting

2024-513613-12-00 Part A: Healthy volunteers (Part A is not applicable to 2025-09-18
Evaluation of efficacy and safety of GSK5764227 (alone and in combination) in participants with previously treated advanced unresectable or … Recruiting

2025-520672-26-00 Gastrointestinal Neoplasms 2025-09-16
A pilot, multicentre, controlled, open-label study evaluating 24 months of lithium carbonate treatment in patients with TBR1-related neuroco… Recruiting

2024-513955-34-00 Proven pathogenic or probably pathogenic TBR1 variant 2025-09-09
PANCEP-1 Recruiting

2023-506979-10-00 Pancreatic cancer 2025-09-02
A clinical study of ifinatamab deruxtecan and pembrolizumab with or without chemotherapy in people with esophageal cancer (MK-3475-06E) Recruiting

2024-514273-22-00 Esophageal squamous cell carcinoma 2025-09-02
A clinical study of combination therapies in people with kidney cancer (MK-3475-03C) Recruiting

2024-516437-12-00 Clear cell renal cell carcinoma 2025-08-29
PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS Recruiting

2024-514954-63-00 RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS 2025-08-20
Pomalidomide in people with chronic hepatitis B virus (HBV) infection: Safety and immune-enhancing effects (The PIPPI Study) Recruiting

2025-521030-29-00 Hepatitis B virus infection 2025-08-19
Safety and Preliminary Clinical Efficacy of MT-302 with CapOx based regimens in metastatic esophagogastric cancer (SPaCE-MT) Recruiting

2024-520213-45-00 metastatic esophagogastric cancer 2025-08-15
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Metastatic castrate resistant prostate cancer - mCRPC 2025-08-12
A Phase I/II Double-blind, randomized, placebo-controlled trial to preserve residual insulin secretion in children with recent onset Type 1 … Recruiting

2024-515106-30-00 Type 1 diabetes 2025-08-06
A phase I/II study of CAR-expressing Allogenic iPSC derived NK cells for treatment of autoiMmune disease by B cELl depletion - CARAMEL Recruiting

2024-519532-16-00 Idiopathic inflammatory myositis 2025-07-30
A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Recruiting

2024-512146-41-00 Multiple Myeloma 2025-07-29
An open-label study to assess safety, efficacy, and cellular kinetics of YTB323 in treatment-resistant generalized myasthenia gravis Recruiting

2024-513589-20-00 Treatment-resistant generalized Myasthenia Gravis 2025-07-29
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib … Recruiting

2025-520743-33-00 Advanced/metastatic colorectal cancer 2025-07-23
A clinical trial applying Regulatory T cells in liver transplant recipients to investigate the safety and tolerability when stopping standar… Recruiting

2023-508261-32-00 Solid organ transplantation (Liver) 2025-07-21
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Patients Treated for Blood Cancers Recruiting

2024-518829-15-00 previously untreated chronic lymphocytic leukemia (CLL) 2025-07-02